Company Overview and News

4
ADMA / ADMA Biologics Inc null (Current Report)

2018-10-17 sec.gov - 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

1
ADMA / ADMA Biologics Inc null (Current Report)

2018-10-11 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

 
ADMA Biologics Provides Regulatory Update for BIVIGAM®

2018-10-11 globenewswire
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that it has received a formal communication from the U.
ADMA

3
ADMA / ADMA Biologics Inc null (Current Report)

2018-10-03 sec.gov - 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

2
ADMA / ADMA Biologics Inc null (Current Report)

2018-10-01 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

 
ADMA / ADMA Biologics Inc null

2018-09-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
ADMA

1
ADMA Biologics: Finish Line Ahead?

2018-09-06 seekingalpha - 1
Today we will revisit ADMA Biologics, a small biotech whose stock has rallied recently to nearly $7.00 a share.
CMXHF ADMA

2
ADMA / ADMA Biologics Inc null (Current Report)

2018-09-05 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

 
ADMA / ADMA Biologics Inc null (Current Report)

2018-09-05 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

 
ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved

2018-09-05 globenewswire
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain infectious diseases, announces that the United States Food and Drug Administration (“FDA”) inspection database classification website has been updated and confirms ADMA’s compliance status has improved to Voluntary Action Indicated (“VAI”).
ADMA

 
ADMA Biologics: Buy Or Sell Before Bivigam PDUFA?

2018-08-31 seekingalpha
ADMA Biologics shares are already up 10% in less than a week since the trade was mentioned to subscribers of the premium Marketplace service. Shares have more upside ahead.
ADMA

2
ADMA / ADMA Biologics Inc null (Current Report)

2018-08-27 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

 
ADMA Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-27 globenewswire
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases, announces that President and Chief Executive Officer, Adam Grossman, and Executive Vice President and Chief Financial Officer, Brian Lenz, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.
ADMA

 
Revisiting ADMA Biologics

2018-08-24 seekingalpha
ADMA Biologics recently announced that the FDA had set an October 25, 2018, PDUFA Date for Bivigam.
CMXHF ADMA

 
ADMA / ADMA Biologics Inc null (Quarterly Report)

2018-08-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
ADMA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ADMA / ADMA Biologics Inc on message board site Silicon Investor.

ADMA - http://www.admabiologics.com/ ADMA - http://www.admabiologics.com/ ADMA - http://www.admabiologics.com/
CUSIP: 000899104